DB17405ExperimentalCell transplant therapies
LuLym-T is an investigational autologous immune cell therapy consisting of activated T Lymphocytes. Developed by Lukas Biomedical, Inc., it is currently being investigated in hepatocellular carcinoma.
- Also known as
- Autologous Activated T Lymphocytes (ATL)
Which companies are running trials of LuLym-T, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account